| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.005 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.12 | 0.3 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.11 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.11 | 0.4 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.1 | 0.4 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.2 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.006 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.008 |